biotech / news / / The Boston Globe
CREATE Medicines has raised another $122 million from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and others.
CREATE Medicines raised $122 million in Series B funding to advance its in vivo CAR-T pipeline.
KEY POINTS
- CREATE rebranded from Myeloid Therapeutics last fall and expanded into autoimmune disease research.
- CREATE's CAR-T therapies are generated directly inside patients, unlike traditional off-site engineered CAR-T.
- CREATE plans to request regulatory approval soon for its first autoimmune therapy clinical trial.
- Preclinical data shows CREATE's therapies demonstrate strong B-cell suppression relevant to autoimmune diseases.
COMPANIES
Summarized by Newsio from The Boston Globe. How we summarize →